$ICLR

CLIMAX JOHN DR sold $138K of ICLR

CLIMAX JOHN DR sold 841 shares of ICON PLC (ICLR) at an average of $164.29 ($162.72–$165.51, $0.14M total) across 4 trades on 2026-08-11.

Original reporting
SEC EDGAR · CLIMAX JOHN DR
Published Aug 12, 2026, 8:47 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ICLR
Neutral
medium confidence
Mentioned
$ICLR
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ICLRNeutralLow
01

Why it matters

A director’s open-market sale may slightly pressure sentiment, but without any new company-specific operational or financial information, it is unlikely to drive a sustained repricing.

02

Market read

Traders may note insider selling, but there is no accompanying fundamental update in the filing text.

03

What to watch

The article does not state motivations, tax events, or whether other insiders are buying, so the signal strength is weak.

Relevance 4/10Novelty 3/10Timing: filed Aug 12, covering Aug 11 sale trades

Background

The article is a SEC Form 4 insider transaction for ICON PLC, reported by a director.

Company-level read

Ticker impact

$ICLRNeutralMedium confidence
Context

ICON PLC director CLIMAX JOHN DR filed a Form 4 open-market sale of 841 shares at about $164.29 weighted average.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

This is a routine Form 4 disclosure with no 10b5-1 plan and no accompanying company-specific news, contract, or guidance change.

Market effects

Minimal, as the disclosure does not indicate sector-wide regulatory, clinical, or demand changes.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for diversification or liquidity needs and may not reflect negative expectations.

Key entities

  • ICON PLC

    The company whose director insider sale is disclosed on Form 4.

  • CLIMAX JOHN DR

    Director who sold 841 shares across four trades on Aug 11.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ICLRMedAI 9/10

ICON plc: ICON Reports Second Quarter 2026 Results

ICON plc (NASDAQ: ICLR) reported Q2 2026 results. Revenue was $2,063.5 million, up 1.4% QoQ. Adjusted EBITDA was $327.2 million (15.9% of revenue). GAAP net income was $72.6 million ($0.94 diluted EPS) and adjusted net income was $198.4 million ($2.56 adjusted EPS). Net business wins were $3,120 million, backlog $23.4 billion, and it reaffirmed 2026 guidance.

$ICLRHighAI 8/10

ICON PLC (ICLR): Financial results for Q2 2026

ICON PLC (ICLR) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 ICON Reports Second Quarter 2026 Results Highlights • Quarter two revenue of $2,063.5 million, an increase of 1.4% on quarter one 2026. • Quarter two adjusted EBITDA of $327.2 million or 15.9% of revenue, an increase of 3.0% on quarter one 2026. • GAAP net income for

$ICLRMed

ICON stock surges 7% on Anthropic AI partnership for trials By Investing.com

ICON plc (NASDAQ:ICLR) shares rose about 7.8% after the company announced a multi-year partnership with Anthropic to integrate Claude AI into its Orbis clinical trial platform. ICON said the collaboration will add four production capabilities, including site intelligence and enrollment risk detection, and will roll out Claude across roles. ICON cited enrollment delays affecting up to 80% of trials.

$ICLRMed

ICON, Anthropic Sign Multi-Year Partnership Deal To Advance AI Capabilities, Stock Up In Pre-Market

ICON Public Limited Company (ICLR) said it signed a multi-year partnership with Anthropic to integrate Claude AI across the clinical trial lifecycle using ICON’s Orbis platform. ICON plans to work with Anthropic’s life sciences team and deploy Claude Code, Claude, and Claude Science. The company cited CEO Barry Balfe. In pre-market, ICLR rose to $177.69, up 5.28% on Nasdaq.